{"hands_on_practices": [{"introduction": "The development of cancer from a single rogue cell is a process of clonal evolution unfolding over time. This exercise uses a foundational model of population dynamics to estimate the silent latency period of Chronic Myeloid Leukemia (CML), from the initial $BCR$-$ABL1$ fusion event to the point of clonal dominance within a local niche. By deriving the time to expansion from first principles, you will gain a quantitative appreciation for the long timescale of CML's development before it becomes clinically detectable [@problem_id:4318369].", "problem": "A single hematopoietic progenitor acquires the Breakpoint Cluster Region–ABL1 (BCR-ABL1) fusion in the bone marrow of a person who later develops Chronic Myeloid Leukemia (CML). Consider an effective local niche of actively cycling myeloid progenitors of size $N$, where $N$ represents the number of competitor cells sharing the same proliferative microenvironment. Let $M(t)$ denote the number of BCR-ABL1–positive cells and $W(t)$ denote the number of BCR-ABL1–negative competitor cells at time $t$ (in years). Assume continuous-time exponential dynamics grounded in the standard birth–death approximation for well-mixed populations: the BCR-ABL1 clone has a net Malthusian growth parameter advantage $s$ over background, such that the wild-type population grows with parameter $r$ and the BCR-ABL1 population grows with parameter $r+s$, where $s>0$ reflects the aggregate increase in proliferation and/or survival due to constitutive tyrosine kinase signaling. At $t=0$, a single BCR-ABL1–positive cell appears in the niche, so $M(0)=1$, and the remaining $N-1$ cells are wild-type, so $W(0)=N-1$.\n\nStarting only from these assumptions and definitions, derive an analytic expression for the time $t^{\\ast}$ at which the BCR-ABL1 clone reaches clonal dominance in the niche, defined here as $M(t^{\\ast})=W(t^{\\ast})$. Then, evaluate $t^{\\ast}$ for $N=3000$ and $s=1.2$ per year. Round your numerical answer to three significant figures and express it in years. Finally, briefly interpret how this time scale relates to clinical latency from the initial genomic event to detectable disease by quantitative polymerase chain reaction (qPCR) in precision diagnostics, noting that this interpretive step should not alter your computed numerical answer.", "solution": "The problem asks for the derivation of an analytic expression for the time $t^{\\ast}$ at which a BCR-ABL1–positive clonal population, $M(t)$, achieves dominance over a wild-type competitor population, $W(t)$, within a shared niche of initial size $N$. It also asks for a numerical evaluation of this time and a brief interpretation.\n\nFirst, we establish the mathematical model based on the provided information. The populations are governed by continuous-time exponential growth dynamics. The number of BCR-ABL1–positive cells, $M(t)$, grows with a net Malthusian parameter of $r+s$, while the number of wild-type competitor cells, $W(t)$, grows with a parameter of $r$. Here, $s > 0$ represents the selective growth advantage of the mutant clone. The corresponding differential equations are:\n$$ \\frac{dM}{dt} = (r+s)M(t) $$\n$$ \\frac{dW}{dt} = rW(t) $$\n\nThese are first-order linear ordinary differential equations. Their solutions are exponential functions of time:\n$$ M(t) = M(0) \\exp((r+s)t) $$\n$$ W(t) = W(0) \\exp(rt) $$\n\nThe problem provides the initial conditions at $t=0$. A single BCR-ABL1–positive cell appears, so $M(0)=1$. The niche initially contains $N$ cells in total, with the remainder being wild-type, so $W(0)=N-1$. Substituting these initial conditions into the general solutions yields the specific dynamics for this system:\n$$ M(t) = 1 \\cdot \\exp((r+s)t) = \\exp((r+s)t) $$\n$$ W(t) = (N-1) \\exp(rt) $$\n\nThe problem defines clonal dominance as the time point $t^{\\ast}$ where the number of mutant cells equals the number of wild-type cells, i.e., $M(t^{\\ast}) = W(t^{\\ast})$. We set the two expressions equal to find this time:\n$$ \\exp((r+s)t^{\\ast}) = (N-1) \\exp(rt^{\\ast}) $$\n\nTo solve for $t^{\\ast}$, we can simplify this equation. Using the property of exponents $\\exp(a+b) = \\exp(a)\\exp(b)$, we can rewrite the left-hand side:\n$$ \\exp(rt^{\\ast}) \\exp(st^{\\ast}) = (N-1) \\exp(rt^{\\ast}) $$\n\nSince $\\exp(rt^{\\ast})$ is strictly positive for any finite $r$ and $t^{\\ast}$, we can divide both sides by this term. This step reveals that the time to dominance is independent of the background growth rate $r$.\n$$ \\exp(st^{\\ast}) = N-1 $$\n\nTo isolate $t^{\\ast}$, we take the natural logarithm, denoted as $\\ln$, of both sides of the equation:\n$$ \\ln(\\exp(st^{\\ast})) = \\ln(N-1) $$\n$$ st^{\\ast} = \\ln(N-1) $$\n\nFinally, we solve for $t^{\\ast}$ to obtain the desired analytic expression:\n$$ t^{\\ast} = \\frac{\\ln(N-1)}{s} $$\n\nNext, we evaluate this expression using the provided numerical values: $N=3000$ and $s=1.2$ per year.\n$$ t^{\\ast} = \\frac{\\ln(3000-1)}{1.2} = \\frac{\\ln(2999)}{1.2} $$\n\nUsing a calculator for the numerical value:\n$$ t^{\\ast} \\approx \\frac{8.006034}{1.2} \\approx 6.671695 \\text{ years} $$\n\nThe problem requires rounding the final answer to three significant figures.\n$$ t^{\\ast} \\approx 6.67 \\text{ years} $$\n\nFinally, for the interpretation, the calculated time $t^{\\ast} \\approx 6.67$ years represents the duration required for a single neoplastic cell to expand to a population size equal to that of its direct competitors within its local microenvironment or niche. This is a model of the pre-clinical latency period, the silent phase of clonal evolution following the initiating oncogenic event. At time $t^{\\ast}$, the number of BCR-ABL1 cells is $M(t^{\\ast}) = N-1 = 2999$. This cell count is far below the threshold for systemic disease detection by standard clinical methods like quantitative polymerase chain reaction (qPCR), which typically require a much larger total tumor burden (e.g., $>10^5$ to $10^6$ cells). Therefore, this calculated time scale represents only a fraction of the total time from the initial mutation to clinical diagnosis. The full clinical latency would also include the subsequent time required for the clone to grow from this state of local dominance to a macroscopically detectable, systemic disease burden, potentially involving dissemination to and colonization of other niches. The result is nonetheless biologically plausible, as CML is known to have a long latency period.", "answer": "$$ \\boxed{6.67} $$", "id": "4318369"}, {"introduction": "Once CML is diagnosed and treated, precision monitoring is key to managing the disease and assessing the efficacy of targeted therapies. This practice focuses on the essential task of translating raw quantitative PCR data into a clinically meaningful value on the International Scale (IS). Mastering this calculation is fundamental for determining whether a patient has achieved a critical therapeutic milestone like Major Molecular Response (MMR), a cornerstone of modern CML care [@problem_id:4318375].", "problem": "In chronic myeloid leukemia, molecular response is monitored by quantifying the BCR-ABL1 fusion transcript relative to a control gene (typically ABL1) using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Standardized reporting uses the International Scale (IS), which is established by laboratories through calibration against reference panels, yielding a laboratory-specific conversion factor that maps the measured transcript ratio onto the IS. Major Molecular Response (MMR) is defined as achieving a transcript level of $\\le 0.1\\%$ on the International Scale (IS), which corresponds to a final ratio (after applying the conversion factor) of $\\le 0.001$.\n\nA patient's assay yields $BCR\\text{-}ABL1 = 120$ copies and $ABL1 = 180{,}000$ copies, with a laboratory conversion factor $CF = 0.5$. Using foundational definitions that (i) the relative disease burden is estimated by the ratio of fusion transcript copies to control gene copies, and (ii) the conversion factor calibrates this ratio to the International Scale, compute the patient's IS-calibrated ratio as a decimal fraction. Then, determine whether the patient achieves Major Molecular Response based on the MMR threshold stated above. Round your reported International Scale value to four significant figures. Report only the IS-calibrated ratio (as a single number) in your final answer box.", "solution": "The solution involves two main steps: first, calculating the raw ratio of BCR-ABL1 transcripts to the ABL1 control transcripts, and second, applying the laboratory's conversion factor (CF) to obtain the final ratio on the International Scale (IS).\n\nLet $N_{BCR\\text{-}ABL1}$ be the number of copies of the $BCR\\text{-}ABL1$ fusion transcript and $N_{ABL1}$ be the number of copies of the $ABL1$ control gene transcript. The given values are:\n$$ N_{BCR\\text{-}ABL1} = 120 $$\n$$ N_{ABL1} = 180{,}000 $$\n\nFirst, we calculate the laboratory's raw transcript ratio, which we can denote as $R_{\\text{lab}}$:\n$$ R_{\\text{lab}} = \\frac{N_{BCR\\text{-}ABL1}}{N_{ABL1}} = \\frac{120}{180{,}000} = \\frac{1}{1500} $$\n\nNext, we apply the laboratory-specific conversion factor, $CF = 0.5$, to calibrate this raw ratio to the International Scale. Let's call the resulting value the IS-calibrated ratio, $R_{\\text{IS}}$:\n$$ R_{\\text{IS}} = R_{\\text{lab}} \\times CF $$\nSubstituting the values for $R_{\\text{lab}}$ and $CF$:\n$$ R_{\\text{IS}} = \\left(\\frac{1}{1500}\\right) \\times 0.5 = \\frac{0.5}{1500} = \\frac{1}{3000} $$\n\nTo express this as a decimal, we perform the division:\n$$ R_{\\text{IS}} = 1 \\div 3000 = 0.0003333\\overline{3} $$\nThe problem requires rounding this value to four significant figures. The first significant figure is the first non-zero digit (the 3 in the ten-thousandths place). The first four significant figures are 3333. The digit following the fourth significant figure is 3, which is less than 5, so we round down (i.e., truncate).\nThe IS-calibrated ratio rounded to four significant figures is:\n$$ R_{\\text{IS}} \\approx 0.0003333 $$\n\nFinally, we determine if the patient has achieved Major Molecular Response (MMR). The problem states that the threshold for MMR corresponds to a final ratio of $\\le 0.001$. We compare our calculated ratio to this threshold:\n$$ 0.0003333 \\le 0.001 $$\nThis inequality is true. Therefore, the patient has achieved Major Molecular Response. The final answer to be reported is the calculated numerical ratio.", "answer": "$$\\boxed{0.0003333}$$", "id": "4318375"}, {"introduction": "The ultimate goal of CML therapy is to achieve a deep and durable molecular response, pushing the disease to levels near or below the limit of detection. This advanced practice tackles the statistical challenges of classifying deep responses like MR$4.5$, where random assay variability can easily lead to misclassification. You will evaluate different laboratory decision rules, balancing the need to avoid false alarms with the goal of correctly identifying patients who have reached this profound level of remission, a scenario that demands statistical rigor in diagnostic design [@problem_id:4318371].", "problem": "A molecular diagnostics laboratory quantifies Breakpoint Cluster Region-Abelson $1$ (BCR-ABL$1$) transcripts in chronic myeloid leukemia on the International Scale (IS) using Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR). On the IS, major molecular response categories are defined by transcript ratio thresholds: MR$4$ corresponds to BCR-ABL$1$/control gene $\\leq$ $0.01\\%$, and MR$4.5$ corresponds to $\\leq$ $0.0032\\%$. At low transcript levels, multiplicative sources of error from reverse transcription efficiency, amplification efficiency, and calibrator uncertainty make the log$_{10}$-transformed IS ratio approximately Gaussian across technical replicates. Assume the following foundational model and facts:\n- The log$_{10}$ of the measured IS ratio, $Y$, for a single technical replicate is distributed as $Y \\sim \\mathcal{N}(\\mu, \\sigma^{2})$ with replicate-to-replicate independence for a given extract. Here $\\mu$ is the true log$_{10}$ IS ratio and $\\sigma$ summarizes assay variability from extraction through RT-qPCR. In well-calibrated laboratories at low IS levels, a typical per-replicate $\\sigma$ is about $0.12$ log$_{10}$-units.\n- For classification, the laboratory compares $Y$ to fixed log$_{10}$ thresholds $t_{4}$ and $t_{4.5}$ corresponding to MR$4$ and MR$4.5$ on the IS, respectively. Equivalently, comparing the untransformed IS value to $0.01\\%$ (MR$4$) and $0.0032\\%$ (MR$4.5$).\n- Independent technical replicates can be used to reduce decision error, and independent biological confirmation on a subsequent blood draw reduces the chance of a transient or stochastic false categorization.\n\nConsider a patient whose true IS ratio is $0.005\\%$, which is below the MR$4$ threshold but above the MR$4.5$ threshold. Let $\\mu = \\log_{10}(0.00005)$, $t_{4.5} = \\log_{10}(0.000032)$, and per-replicate $\\sigma = 0.12$. Using only the normality assumption on log$_{10}$-IS and independence across technical replicates, reason from first principles to quantify how assay variability near the MR$4.5$ boundary impacts misclassification and how replication rules can control it. Then, select the decision rule that simultaneously satisfies all of the following three criteria:\n- Keeps the probability of a false MR$4.5$ call on a single visit at or below $5\\%$ for the patient with true IS $0.005\\%$.\n- Achieves at least $50\\%$ probability of correctly calling MR$4.5$ on a single visit when the true IS equals the MR$4.5$ threshold (i.e., $\\mu = t_{4.5}$).\n- Includes an explicit, independent confirmation step on a subsequent sample to support durable classification at MR$4.5$.\n\nWhich option best meets these criteria while reflecting sound laboratory practice on the International Scale?\n\nA. Call MR$4.5$ on a single technical replicate if its IS is below $0.0032\\%$ or undetectable with adequate control gene input; no confirmation required if internal controls pass.\n\nB. Perform $2$ technical replicates on one sample; call MR$4.5$ only if both replicates are below $0.0032\\%$; confirm within $4$ weeks on a new blood draw requiring any single replicate below $0.0032\\%$.\n\nC. Perform $3$ technical replicates on one sample; call MR$4.5$ if at least $2$ of $3$ replicates are below $0.0032\\%$; confirm within $4$–$12$ weeks on an independent sample meeting the same $2$ of $3$ rule and adequate control gene copy criteria.\n\nD. Perform $2$ technical replicates; compute the average of the two log$_{10}$-IS values and call MR$4.5$ if this average is below $\\log_{10}(0.000032)$; no further confirmation is necessary if the control gene copy number exceeds prespecified acceptance thresholds.", "solution": "The problem requires the evaluation of four different decision rules for classifying a patient as having achieved Major Molecular Response $4.5$ (MR$4.5$) in chronic myeloid leukemia (CML) monitoring. The evaluation is based on three specific criteria related to statistical error rates and laboratory practice.\n\nFirst, we formalize the problem. Let $R$ be the measured IS ratio. The problem states that $Y = \\log_{10}(R)$ is a normally distributed random variable, $Y \\sim \\mathcal{N}(\\mu, \\sigma^2)$, where $\\mu$ is the true log$_{10}$-transformed IS ratio and $\\sigma$ is the standard deviation of the measurement on the log$_{10}$ scale.\nThe given parameters are:\n- Standard deviation per replicate: $\\sigma = 0.12$.\n- The MR$4.5$ threshold is a ratio of $0.0032\\%$, which is $0.000032$.\n- The corresponding threshold on the log$_{10}$ scale is $t_{4.5} = \\log_{10}(0.000032) = \\log_{10}(3.2 \\times 10^{-5}) \\approx -4.49485$.\n\nA decision rule makes a call of MR$4.5$. We must evaluate each proposed rule against three criteria.\n\n### Criterion 1: False Positive Rate\nThe probability of a false MR$4.5$ call must be at or below $5\\%$ ($\\leq 0.05$) for a patient whose true IS ratio is $0.005\\%$, which is $0.00005$.\nFor this patient, the true mean of the log-ratio is $\\mu_1 = \\log_{10}(0.00005) = \\log_{10}(5 \\times 10^{-5}) \\approx -4.30103$.\nLet's calculate the probability, $p_1$, that a single replicate from this patient falls below the MR$4.5$ threshold:\n$$ p_1 = P(Y < t_{4.5} \\mid \\mu = \\mu_1) $$\nTo calculate this, we standardize the variable. Let $Z \\sim \\mathcal{N}(0, 1)$ be the standard normal variable.\n$$ p_1 = P\\left( \\frac{Y - \\mu_1}{\\sigma} < \\frac{t_{4.5} - \\mu_1}{\\sigma} \\right) = P\\left( Z < \\frac{-4.49485 - (-4.30103)}{0.12} \\right) $$\n$$ p_1 = P\\left( Z < \\frac{-0.19382}{0.12} \\right) \\approx P(Z < -1.615) $$\nUsing a standard normal distribution cumulative density function, $\\Phi(-1.615) \\approx 0.0531$.\nSo, for any single replicate, the probability of it being below the threshold is $p_1 \\approx 5.31\\%$.\n\n### Criterion 2: Statistical Power (Sensitivity)\nThe probability of a correct MR$4.5$ call must be at least $50\\%$ ($\\geq 0.50$) when the patient's true IS ratio is exactly at the threshold, i.e., $0.0032\\%$.\nFor this scenario, the true mean of the log-ratio is $\\mu_2 = t_{4.5} \\approx -4.49485$.\nLet's calculate the probability, $p_2$, that a single replicate from this patient falls below the MR$4.5$ threshold:\n$$ p_2 = P(Y < t_{4.5} \\mid \\mu = t_{4.5}) $$\n$$ p_2 = P\\left( \\frac{Y - t_{4.5}}{\\sigma} < \\frac{t_{4.5} - t_{4.5}}{\\sigma} \\right) = P(Z < 0) = 0.5 $$\nSo, for any single replicate from a patient whose true value is at the threshold, the probability of it being below the threshold is exactly $p_2 = 50\\%$.\n\n### Criterion 3: Confirmation\nThe decision rule must include an explicit, independent confirmation step on a subsequent sample.\n\nNow, we evaluate each option based on its performance on a single visit for the first two criteria and its inclusion of the third.\n\n**Option A: Call MR$4.5$ on a single technical replicate if its IS is below $0.0032\\%$. No confirmation required.**\n- **Criterion 1 (False Positive $\\leq 5\\%$):** The probability of a false call is the probability that a single replicate is below the threshold, which is $p_1 \\approx 0.0531$ or $5.31\\%$. Since $5.31\\% > 5\\%$, this criterion is **not met**.\n- **Criterion 2 (Power $\\geq 50\\%$):** The probability of a correct call is the probability that a single replicate is below the threshold, which is $p_2 = 0.5$ or $50\\%$. This criterion is **met**.\n- **Criterion 3 (Confirmation):** The rule explicitly states \"no confirmation required\". This criterion is **not met**.\n**Verdict for A:** Incorrect.\n\n**Option B: Perform $2$ technical replicates; call MR$4.5$ only if both are below $0.0032\\%$. Confirmation required.**\n- **Criterion 1 (False Positive $\\leq 5\\%$):** Let $Y_1, Y_2$ be the results of two independent replicates. A false call occurs if $Y_1 < t_{4.5}$ AND $Y_2 < t_{4.5}$. The probability is $p_1 \\times p_1 = p_1^2$.\n$P(\\text{False Call}) = (0.0531)^2 \\approx 0.00282$, or $0.282\\%$. Since $0.282\\% \\leq 5\\%$, this criterion is **met**.\n- **Criterion 2 (Power $\\geq 50\\%$):** A correct call occurs if $Y_1 < t_{4.5}$ AND $Y_2 < t_{4.5}$ for a patient with $\\mu = t_{4.5}$. The probability is $p_2 \\times p_2 = p_2^2$.\n$P(\\text{Correct Call}) = (0.5)^2 = 0.25$, or $25\\%$. Since $25\\% < 50\\%$, this criterion is **not met**.\n- **Criterion 3 (Confirmation):** The rule includes a confirmation step. This criterion is **met**.\n**Verdict for B:** Incorrect.\n\n**Option C: Perform $3$ technical replicates; call MR$4.5$ if at least $2$ of $3$ are below $0.0032\\%$. Confirmation required.**\n- **Rule:** This follows a binomial distribution. Let $X$ be the number of replicates below the threshold out of $n=3$ trials. The probability of a call is $P(X \\geq 2) = P(X=2) + P(X=3)$.\nUsing the binomial probability formula $P(X=k) = \\binom{n}{k}p^k(1-p)^{n-k}$:\n$P(X \\geq 2) = \\binom{3}{2}p^2(1-p)^1 + \\binom{3}{3}p^3(1-p)^0 = 3p^2(1-p) + p^3$.\n- **Criterion 1 (False Positive $\\leq 5\\%$):** We use $p = p_1 \\approx 0.0531$.\n$P(\\text{False Call}) = 3(0.0531)^2(1-0.0531) + (0.0531)^3$\n$P(\\text{False Call}) \\approx 3(0.00282)(0.9469) + 0.00015 \\approx 0.00801 + 0.00015 = 0.00816$.\nThis probability is $0.816\\%$, which is well below $5\\%$. This criterion is **met**.\n- **Criterion 2 (Power $\\geq 50\\%$):** We use $p = p_2 = 0.5$.\n$P(\\text{Correct Call}) = 3(0.5)^2(1-0.5) + (0.5)^3 = 3(0.25)(0.5) + 0.125 = 0.375 + 0.125 = 0.5$.\nThe probability is $50\\%$. Since $50\\% \\geq 50\\%$, this criterion is **met**.\n- **Criterion 3 (Confirmation):** The rule explicitly includes confirmation on an independent sample. This criterion is **met**.\n**Verdict for C:** Correct.\n\n**Option D: Perform $2$ technical replicates; average the log$_{10}$-IS values and call MR$4.5$ if the average is below $\\log_{10}(0.000032)$. No confirmation necessary.**\n- **Rule:** Let $\\bar{Y} = (Y_1+Y_2)/2$. The mean of $\\bar{Y}$ is $\\mu$ and its variance is $\\sigma^2/2$. So the standard deviation of $\\bar{Y}$ is $\\sigma_{\\bar{Y}} = \\sigma/\\sqrt{2} = 0.12/\\sqrt{2} \\approx 0.08485$.\n- **Criterion 1 (False Positive $\\leq 5\\%$):** We test $P(\\bar{Y} < t_{4.5})$ for $\\mu = \\mu_1 \\approx -4.30103$.\n$P(\\text{False Call}) = P\\left( Z < \\frac{t_{4.5} - \\mu_1}{\\sigma_{\\bar{Y}}} \\right) = P\\left( Z < \\frac{-4.49485 - (-4.30103)}{0.08485} \\right)$\n$P(\\text{False Call}) \\approx P\\left( Z < \\frac{-0.19382}{0.08485} \\right) \\approx P(Z < -2.284)$.\n$\\Phi(-2.284) \\approx 0.0112$. This probability is $1.12\\%$, which is below $5\\%$. This criterion is **met**.\n- **Criterion 2 (Power $\\geq 50\\%$):** We test $P(\\bar{Y} < t_{4.5})$ for $\\mu = \\mu_2 = t_{4.5}$.\n$P(\\text{Correct Call}) = P\\left( Z < \\frac{t_{4.5} - t_{4.5}}{\\sigma_{\\bar{Y}}} \\right) = P(Z < 0) = 0.5$.\nThe probability is $50\\%$. This criterion is **met**.\n- **Criterion 3 (Confirmation):** The rule states \"no further confirmation is necessary\". This criterion is **not met**.\n**Verdict for D:** Incorrect.\n\nIn summary, only Option C satisfies all three required criteria. It provides a low false positive rate for a patient just outside the MR$4.5$ response category, sufficient power to detect a patient who is truly at the boundary, and incorporates the sound laboratory practice of confirming a significant clinical finding on a new biological sample.", "answer": "$$\\boxed{C}$$", "id": "4318371"}]}